Quantitative biometrics will be established using company’s integrated pathology approach.
Aureon Laboratories will establish quantitative biometrics to assess therapeutic responses in studies focusing on prostate cancer for Pfizer. The collaboration will utilize Aureon’s integrated systems pathology approach, whereby data generated from tissue morphometry, multiplexed-protein biomarkers, and in situ RNA expression are integrated with patient clinical information and associated with clinical outcome.
The deal is an extension of a previous study performed by Aureon and Pfizer to evaluate prostatectomy samples from patients treated with neo-adjuvant androgen deprivation therapy (ADT).
Aureon technology is also being used to develop Prostate Px+. This prognosticwill be used in men newly diagnosed with prostate cancer. The companies expect the product to be released this year.